iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/6137354
Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1983 Sep;26(3):191-211.
doi: 10.2165/00003495-198326030-00002.

Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy

J K Errick, R C Heel
Review

Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy

J K Errick et al. Drugs. 1983 Sep.

Abstract

Nalbuphine is an agonist/antagonist analgesic. After parenteral administration of 'usual' doses it is approximately equipotent in analgesic activity to morphine on a weight basis. In studies in patients with moderate to severe pain, usually following surgery, the characteristics of analgesia with nalbuphine were comparable to those seen with equianalgesic doses of morphine or pentazocine. It also appears to produce satisfactory anaesthesia when used as a component of a 'balanced' anaesthesia technique, although a relatively low 'ceiling' effect for reduction of anaesthetic requirements with nalbuphine may limit its usefulness in this regard. As with other agonist/antagonist analgesics, a 'ceiling' effect to nalbuphine-induced respiratory depression is also seen, beyond which further depression does not readily occur. However, with usual analgesic doses, respiratory depression seen with nalbuphine is comparable to that with morphine. Important haemodynamic changes have not occurred after usual doses of nalbuphine, even in patients with cardiac disease. Like other agonist/antagonist analgesic drugs, the abuse potential of nalbuphine seems relatively low, but only wider clinical use for longer periods can establish this with certainty. Thus, nalbuphine appears to offer a useful alternative to morphine in patients with moderate to severe pain.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cardiovasc Dis. 1978 Mar;5(1):19-24 - PubMed
    1. Am J Med. 1976 Jun;60(7):949-55 - PubMed
    1. Ann Ophthalmol. 1983 Jan;15(1):64-6 - PubMed
    1. Br Heart J. 1965 Nov;27(6):863-75 - PubMed
    1. Adv Biochem Psychopharmacol. 1973;8(0):319-34 - PubMed

LinkOut - more resources